KR100863615B1 - Skincare composition containing priprioca oil - Google Patents

Abstract

A composition comprising priprioca oil is provided to show excellent melanogenesis inhibitory efficiency, collagen synthesis promoting capability and collagenase activity inhibitory activity, be safely applied to skin without any toxicity and irritation, and have skin whitening effect, inflammation inhibitory effect, immunity inhibitory effect, anti-oxidative effect, anti-obese effect and hair growth effect, thereby being usefully used for a cosmetic, a medicine or a food. A composition for improving wrinkles, skin whitening, anti-obesity, inhibiting immunity, promoting hair growth, preventing hair loss or anti-oxidizing comprises 0.0001-10 wt.% of priprioca oil as an effective ingredient. The composition is a cosmetic composition or a pharmaceutical composition. Further, the cosmetic composition is a form selected from solution, paste, gel, cream, lotion, soap, surfactant-comprised cleansing, oil, powder foundation, wax foundation and spray.

Description

Skin composition containing priprioca oil {Skincare composition containing priprioca oil}

Figure 1 shows the effect of inhibiting melanogenesis in B16 melanoma cells by priprioca oil (priprioca oil).

Figure 2 shows the results of the collagen biosynthesis promoting effect by the priprioca oil (RA: retinoic acid 1 uM).

Figure 3 shows the free radical scavenging effect by the priprioca oil (priprioca oil).

The present invention relates to a composition for skin, and more particularly, excellent product stability and can be safely used without side effects on the skin, wrinkle improvement effect, skin whitening effect, anti-obesity effect, immunomodulatory effect, hair loss prevention and hair growth effect It relates to a composition for skin comprising priprioka.

Wrinkles are the result of aging of the skin, and aging skin is the aggregate of natural changes associated with the process of aging. Skin aging is classified into two types, and it is classified into physiological aging, which shows a change in skin function and structure related to age, and photoaging due to ultraviolet rays.

As the skin ages, the changes in the dermis are remarkable. Dermis atrophy that occurs after the age of 70 is a representative aging phenomenon. Changes in the dermis are caused by changes in substances with large molecular weight in the extracellular matrix due to a decrease in the number of fibroblasts and their ability to synthesize. Specific changes include separation of collagen bundles, reduced point polysaccharide synthesis, decreased collagen and elastic fiber counts and diameters, grinding collagen and elastic fibers, and expansion of blood vessels. Generally, among the various factors such as skin moisture content, collagen content, and ability to immunize the external environment, the biggest influence on wrinkle formation is collagen, a collagen degrading enzyme that reduces collagen production and collagen content. It is the expression level and activity of genease. The effect of preprioka oil on collagen and collagenase enzymes is not known. However, this experiment showed that priprioka oil increased collagen synthesis and inhibited collagenase enzyme.

Human skin color is determined by the concentration and distribution of melanin inside the skin. Melanin pigment produced by melanocytes of human skin is a phenolic polymer having a complex form of black pigment and protein, and plays an important role in preventing skin damage caused by ultraviolet rays. It is reported that the action of tyrosinase in melanocytes is the most important for melanin biosynthesis, and tyrosinase is a kind of amino acid tyrosine (DOPA) and dopaquinone (intermediates of melanin polymer production). It plays a key role in the skin darkening process.

Hormonal imbalance is aggravating due to environmental pollution and automobile exhaust gas. As a result, the incidence of hair loss increases, the age of incidence decreases, and the skin immune system is mismatched, causing various skin diseases such as atopy and psoriasis. In addition, the population suffering from obesity is rapidly increasing despite the age of children due to the changes in the diet of meat and meat.

Therefore, in-depth research on the development of substances that can effectively solve various phenomena that are not only aesthetic but also serious social problems, such as aging, wrinkling caused by UV rays, blemishes or freckles, obesity, immune imbalance, and hair loss It is becoming.

Under these backgrounds, the present inventors searched for active substances in natural plants in order to find cosmetics having high safety and stability and excellent skin-related efficacy, while preprioca oil had various effects including whitening, wrinkles, and the like. It was confirmed that safety and stability were excellent.

Free pre-Oka oil Cyperus in Cyperaceae and articulatus L is extracted from the plant roots. Plants of the Cyperaceae family are found primarily in the tropical Amazon forests of Brazil, and more widely in tropical regions of the southern United States and Africa. Priprioka oil is used as a fragrance because of its unique fragrance, and known effects include digestive improvement, emotional stability, and antibacterial effects.

The present inventors endeavored to develop a novel single material having excellent wrinkle stability, whitening effect, anti-obesity effect, hair loss prevention and hair growth effect, antioxidant effect, immunomodulatory effect and high stability, and no skin side effects. Was done.

One object of the present invention is to provide a composition for anti-wrinkle, skin whitening, inflammation inhibitory, anti-obesity, antioxidant, immunosuppressive, hair growth and hair loss containing priprioca oil (priprioca oil). .

Another object of the present invention is to provide a cosmetic composition for anti-wrinkle, skin whitening, inflammation inhibitory, anti-obesity, antioxidant, immunosuppressive, hair growth and hair loss prevention comprising the composition.

Another object of the present invention is to provide a pharmaceutical composition for wrinkle improvement, skin whitening, inflammation inhibition, anti-obesity, antioxidant, immunosuppression, hair growth and hair loss prevention comprising the composition.

In one embodiment, the present invention relates to a composition for anti-wrinkle, skin whitening, anti-inflammatory, anti-obesity, antioxidant, immuno-suppressive, hair growth and hair loss containing priprioca oil (priprioca oil) .

The priprioka oil of the present invention can be prepared separately from natural sources ( Cyperus articulatus L ). For example, the priprioka oil of the present invention is Cyperus The essential oil of articulatus L is separated by steam distillation or compression, and such extraction and separation methods are well known to those skilled in the art.

In order to examine the various skin-related effects of the priprioka oil of the present invention, experiments using various types of efficacy measurement methods commonly used, the melanin production inhibitory effect was superior to the arbutin known as a whitening agent, wrinkle improvement Inhibition of inflammation, immunomodulation, anti-obesity effect, antioxidant effect was found. Therefore, it was found that the priprioka oil of the present invention has various effects as well as the wrinkle improvement effect.

In the dermatological composition of the present invention, the amount of preprioca oil is preferably 0.0001 to 10% by weight based on the total composition. When the amount is less than 0.00001% by weight, the skin-related efficacy is too weak, and when the amount is more than 15% by weight, the increase in effect due to the increase of the content is insufficient and the stability of the formulation is not secured. More preferably, the priprioka oil is contained in 0.0001 to 5% by weight based on the total composition.

As another aspect, the present invention relates to a cosmetic composition for anti-wrinkle, skin whitening, inflammation inhibitory, anti-obesity, antioxidant, immunosuppressive, hair growth and hair loss prevention comprising the composition.

The cosmetic composition includes ingredients conventionally used in cosmetic compositions in addition to preprioca oil as an active ingredient, and for example, conventional auxiliaries and / or carriers such as antioxidants, stabilizers, solubilizers, vitamins, pigments and flavorings. It includes. In addition, the cosmetic composition may further include a skin absorption promoting material to enhance the wrinkle improvement effect.

The cosmetic composition of the present invention may be prepared in any formulation commonly prepared in the art, for example, solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, soaps, surfactant-containing cleansing , Oils, powder foundations, emulsion foundations, wax foundations and sprays, and the like, but are not limited thereto. More specifically, it may be prepared in the form of a flexible lotion, nutrition lotion, nutrition cream, massage cream, essence, eye cream, cleansing cream, cleansing foam, cleansing water, pack, spray or powder.

When the formulation of the present invention is a paste, cream or gel, animal oils, vegetable oils, waxes, paraffins, starches, trachants, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicas, talc or zinc oxide may be used as carrier components. Can be.

When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used, in particular in the case of a spray, additionally chlorofluorohydrocarbon, propane Propellant such as butane or dimethyl ether.

When the formulation of the present invention is a solution or emulsion, a solvent, solubilizer or emulsifier is used as the carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 Fatty acid esters of, 3-butylglycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan.

When the formulation of the present invention is a suspension, liquid carrier diluents such as water, ethanol or propylene glycol, suspending agents such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, microcrystals Soluble cellulose, aluminum metahydroxy, bentonite, agar or tracant and the like can be used.

When the formulation of the present invention is a surfactant-containing cleansing agent, the carrier component is aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, fatty acid. Amide ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives or ethoxylated glycerol fatty acid esters and the like can be used.

In the cosmetic composition of the present invention, the amount of preprioca oil may comprise 0.0001 to 10% by weight, preferably 0.0001 to 5% by weight based on the total composition.

As another aspect, the present invention relates to a pharmaceutical composition for wrinkle improvement, skin whitening, inflammation inhibitory, anti-obesity, antioxidant, immunosuppressive, hair growth and hair loss prevention comprising the composition.

In the pharmaceutical composition of the present invention, the amount of preprioca oil may comprise 0.0001 to 10% by weight, preferably 0.0001 to 5% by weight based on the total composition.

The pharmaceutical compositions of the present invention may further comprise suitable carriers, excipients and diluents commonly used in the manufacture of pharmaceutical compositions.

Formulations of the pharmaceutical compositions of the present invention include powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, oral formulations, ointments, creams, external preparations, suppositories, and sterile injectable solutions according to conventional methods. It may be used in any form suitable for pharmaceutical preparations, including.

The pharmaceutical composition according to the present invention can be administered to mammals such as rats, mice, livestock, humans by various routes such as parenteral, oral, and all modes of administration can be expected, for example, oral, It may be administered by rectal or intravenous, intramuscular, subcutaneous, intrauterine dural or intracerebroventricular injection. At this time, as a parenteral route, transdermal administration is preferred, and topical application is most preferred.

The dosage of the preparation varies depending on the subject's age, sex, weight, symptoms, and method of administration, but in the case of external preparations, 1.0 to 3.0 ml per day may be applied 1 to 5 times a day to continue for more than one month. .

In addition, the oral dosage form may vary depending on the age, sex, and weight of the patient, but the amount of 0.1 to 100 mg / kg may be administered once to several times a day. The dosage may also be increased or decreased depending on the route of administration, the severity of the disease, sex, weight, age, and the like. Therefore, the above dosage does not limit the scope of the present invention in any aspect.

Meanwhile, as a result of the cumulative skin irritation test on the priprioka oil in a specific embodiment of the present invention, it was found that priprioka is a natural substance and is harmless to the human body. Therefore, the priprioca oil of the present invention has little toxicity and side effects, and therefore can be used safely even for long-term use, and in particular, it can be safely applied to cosmetic compositions and pharmaceutical compositions as described above.

Hereinafter, the present invention will be described in more detail with reference to the following examples. However, the present invention is not limited thereto.

Example 1: Priprioka  Wrinkle improvement effect of oil

The anti-wrinkle effect can usually be measured as collagen biosynthesis and collagenase degradation inhibition and abnormality test in humans. Human normal fibroblasts (Pacific) were inoculated into 6-well microplates containing DMEM medium (2 × 10 ⁵ cells / well) and incubated at 37 ° C. for 24 hours in a CO ₂ incubator at 5% concentration. . After 24 hours, the medium was removed from each well, the samples were treated by concentration, and then cultured again for 24 hours. After 24 hours, cell media were collected to prepare samples.

The amount of collagen synthesized was determined by the amount of collagen type I C-peptide (PICP) using a collagen type kit (Procollagen Type I C-peptide EIA kit (MK101), Takara, Kyoto, Japan). Was measured. Detailed test methods were performed according to Takara's kit instructions.

An antibody against collagenase was used to measure the activity of collagenase, an enzyme that degrades collagen. Phagebol myristate acetate (PMA) was treated as a substance that induces collagenase activity. The overall assay was performed according to the methods of known commercially available kits. Type I collagenase assay kit (Amersham Biosciences, RPN2629) was used and absorbance was measured with an ELISA reader. The measured standard values were expressed in the form of mean + standard deviation, and the significance was tested by t-test using the SPSS / PC + program. The results are shown in the following table.

Priprioka Oil (1 ppm) Priprioka Oil (10 ppm) Priprioka Oil (50 ppm) Collagen Synthesis Growth Rate (%) 8 16 21 Collagenase inhibition rate (%) 15 25 31

As shown in Table 1, it was found that the priprioka oil has an anti-wrinkle effect.

Example  2: Priprioka  Oily Cosmetic  Wrinkle improvement effect measurement

Wrinkle improvement effect of cosmetics containing priprioka oil was measured through clinical trials. Nourishing cream prepared in Preparation Example A (nourishing cream containing 1%, 2% and 5% of priprioka oil, respectively) and Comparative Preparation Example (nourishing cream containing purified water) was used.

Wrinkle improvement effect was evaluated by measuring skin elasticity change. Skin elasticity was measured in 30 healthy women (25 to 35 years old) under the condition that the temperature is kept constant at a temperature of 24 to 26 ° C. and a humidity of 38 to 40%. After the subject's face was used twice a day for 3 months, it was measured by using a cutometer SEM 474. The criterion of comparison was a relative value of 0 for no skin elasticity and 5 for many cases. The test results are shown in Table 2 below.

Priprioca oil improves skin elasticity Test Items Preparation A (cream containing 1% priprica oil) Preparation A (cream containing 2% priprica oil) Preparation A (Cream containing 5% of priprioka oil) Comparative Preparation A (Cream containing 0% priprica oil) Skin elasticity 2.3 2.56 2.92 1.97

As shown in Table 2, Preparation Example A of the present invention was much better wrinkle improvement effect than the Comparative Preparation Example, the skin elasticity was also improved as the concentration of the priprioka oil increased.

Example  3: Priprioka  Measurement of the inhibitory effect of melanin production by oil

B16 melanoma cells were used to measure the inhibitory effect of melanin production by preprica oil, and this was compared with the inhibitory effect of melanin production by arbutin known to inhibit melanogenesis.

In this experiment, murine melanoma (B-16 F10) cells were inoculated at 1 × 10 ⁵ per well in a 6-well plate with DMEM medium containing 10% FBS (fetal bovine serum), followed by 5% CO _2. And The cells were cultured at 37 ° C. until the cells adhered at least about 80% to the bottom of the well. After incubation, the medium was removed and the sample was replaced with medium diluted to an appropriate concentration and incubated at 5% CO _{2 ,} 37 ° C for 3 days. The concentration range of prepriocaoyl was determined to be 1 μM, 10 μM, 50 μM without cytotoxicity. The cells from which the medium was removed were washed with phosphated buffer saline (PBS) and treated with trypsin to recover the cells. The recovered cells were counted using a hematocytometer, centrifuged at 5,000 to 10,000 rpm for 10 minutes, and then the supernatant was removed to obtain pellets. The cell pellet was dried at 60 ° C., and 100 μl of 1M sodium hydroxide solution containing 10% DMSO was added to obtain intracellular melanin in a 60 ° C. thermostat. Using this solution, the absorbance was measured at 490 nm using a microplate reader to determine the amount of melanin per cell. The results are shown in Table 3 below.

sample Treatment Concentration (ppm) Melanin production inhibition rate (%) Arbutin 50 23 Priprioka Oil 10 55 50 60

As shown in Table 3, it can be seen that the preprioca oil at the treatment concentration is higher than the melanin production inhibition than arbutin.

Example  4 : Priprioka  By oil Intracellular Tyrosinase  Activity Inhibition Effect Measurement

Rat pigment cells (B16 melanoma cells) were used to measure the inhibitory effect of melanin production by preprica oil, and compared with the inhibitory effect of intracellular tyrosinase activity by arbutin known to inhibit melanin production.

In this experiment, murine melanoma (B-16 F1) cells were inoculated in DMEM medium containing 10% of FBS (fetal bovine serum) in 6-well plates at 1 × 10 ⁵ per well and then treated with 5% CO _{2 at} 37 ° C. The cells were incubated under at least about 80% at the bottom of the well. After incubation, the medium was removed, the sample was replaced with a medium diluted to an appropriate concentration, and then incubated for 3 days under 5% CO _{2 ,} 37 ° C. The concentration range of preprioca oil was determined to be 1 μM, 10 μM, 50 μM without cytotoxicity. The cells from which the medium was removed were washed with phosphated buffer saline (PBS) and treated with trypsin to recover the cells. The recovered cells were counted using a hematocytometer, centrifuged at 5,000 to 10,000 rpm for 10 minutes, and then the supernatant was removed to obtain pellets. The cell pellet was pulverized using lysis buffer, and the supernatant was collected by centrifugation at 12,000 rpm for 10 minutes. Using this solution, the absorbance was measured at 492 nm using a microplate reader to determine the cell number tyrosinase activity. The results are shown in Table 4 below.

sample Treatment Concentration (ppm) Melanin production inhibition rate (%) Arbutin 50 19 Priprioka Oil 10 25 50 40

As shown in Table 4 above, it was found that the priprioka oil had higher intracellular tyrosinase inhibition rate than arbutin.

Example  5: Evaluation of the whitening effect at the animal level

Similar to humans, the whitening effect by priprioka oil was measured using brown malto (Tortoiseshell guinea pigs; known as brown guinea pigs) which are known to cause pigmentation by ultraviolet rays.

In order to cause pigmentation due to ultraviolet (UV) in the brown molemoto, a light shielding aluminum foil having a square window of 3 × 3 cm ² is adhered to the skin from which the hair of the brown molemoto coordination is removed, and then SE lamp ( Ultraviolet rays were irradiated with a wavelength of 290-320 nm (Toshiba) (total irradiation energy amount = 1350 mJ / cm ² ). After UV irradiation, the aluminum foil was peeled off and a sample (priprioka oil, and arbutin) was applied in the following manner. Pigmentation appeared 2 or 3 days after the UV irradiation, and reached a peak after about 2 weeks, and each sample was applied therefrom.

The number of coatings was continued once or twice a day for 50 days. Samples were dissolved and diluted with a specific solvent (Propylene Glycol: Ethanol: Water = 5: 3: 2 mixed solvent), coated with a cotton swab, and prepared a control site for necessarily applying a solvent to other sites. Along with the determination of effects, the cumulative stimulus was also observed.

The effect was determined by measuring the degree of black and white of the skin using a color difference meter (Minolta CR2002 chromameter), the results are shown in Table 3 below. L ^* A ^* B ^* color system is used to display color, and L ^* value was used as an index in this invention. L ^* value was calibrated with a standard whiteboard, and L ^* value was measured 5 times or more at one site, and pigmentation was equalized. The difference (ΔL ^* ) of the skin color at the start of application and at the end of application was determined and the effect was determined using this value. The results are shown in Table 3 below.

(Equation 1)

△ L ^* = L ^* value after 00 days application - L ^* value of the coating start date

Comparing the ΔL ^* value with respect to the sample application site and the control site, the effect of the whitening material can be seen.

sample Treatment Concentration (%) Whitening effect (△ L) Priprioka Oil 0.2 0.32 1.0 0.39 Arbutin 1.0 0.36 Control - 0.29

As shown in Table 5, the priprioka oil showed a better whitening effect than arbutin, and the cumulative stimulus was not observed during the test application of the test substance.

Example 6 Safety Confirmation Experiment on Human Skin of Priprioka Oil

In order to confirm that priprioka oil is safe for human skin, skin safety verification experiments were performed. To this end, a cumulative skin irritation test was performed.

Based on squalene, 1%, 5%, and 10% of preprica oil was added, and a total of nine 24-hour cumulative patches were applied every other day to the upper forearm for 30 healthy adults. The test was carried out to determine whether prepriorca oil was irritating to the skin.

The patching method used a fin chamber (Finn chamber, Epitest Ltd, Finland). 15ul of each said skin external preparation was dripped at the chamber, and the patch was performed. The degree of response to the skin each time was scored using Equation 2 below, and the results are shown in Table 6 below.

Average responsiveness = [[response index x responsiveness / total number of subjects x highest score (4 points)] x 100] ÷ number of tests (9 times)

In the reactivity, ± gives 1 point, + gives 2 points, and ++ gives 4 points, and when the average reactivity is less than 3, it is determined as a safe composition.

Test substance Number of subjects with response Average reactivity 1 week 2 weeks 3 weeks Primary Secondary 3rd 4th 5th 6th 7th 8th 9th ± + + + ± + + + ± + + + ± + + + ± + + + ± + + + ± + + + ± + + + ± + + + Control group (squalene) One - - 0 - - --- --- --- --- --- --- --- 0.09 Priprioka Oil (1%) [Test Group 1] One - - 0 - - --- --- --- --- --- --- --- 0.09 Priprioka Oil (5%) [Test Group 2] One - - 0 - - --- --- --- --- --- --- --- 0.09 Priprioka Oil (10%) [Test Group 3] 2 - - 0 - - --- --- --- --- --- --- --- 0.18

In Table 6, the average reactivity of test groups 1, 2, and 3 was 0.09, 0.09, and 0.18, respectively. Therefore, since the average reactivity was less than 3, preprioca oil was determined to be a safe substance for human skin that does not show a distinct cumulative stimulus pattern.

Example 7: Antioxidant Effect

DPPH (1,1-diphenyl-2-picrylhydrazyl) is a colored radical that can directly identify the radical scavenging ability of a sample by color change. First, put 20 ul into a 96-well plate in a sample dissolved in a solvent, put back 200 ul DPU solution 200 ul each, incubation for 30 minutes at room temperature. The amount of DPPH remaining is determined by absorbance measurement at 540 nm. The antioxidant results of the priprioka oil are shown in Table 7 below. In brief, the effect was determined by observing the free radical removal rate by the sample, the presence or absence of antioxidant function.

sample Treatment Concentration (ppm) Free radical removal rate (%) Priprioka Oil 10 One 100 5 1000 26

As shown in Table 7, the priprioka oil was found to have an antioxidant effect.

Example 8: Anti-inflammatory efficacy evaluation

In order to examine the anti-inflammatory effect, COX activity inhibitory activity was performed according to a conventional method in THP-1 cells, which are human monocytes. COX activity was measured according to Method in Enzymology 43, 9 (1994) published by F. J. Van de Ouderaaa and Muytenhek. The COX assay cultures THP-1 cell line and then dispenses the cells in a 24-well plate. The incubation volume per well is adjusted to 500 μl, and lipopolysaccharide (1 μg / ml) and 2 μl of test compound dissolved in the solvents shown in the following table are added, followed by incubation under the same conditions for 24-48 hours. After 24-48 hours, add 1 µl of calcium ionophore and [1-14C] arachidonic acid (in EtOH, 0.1 µCi / ml) to each well and incubate for 10 minutes under the same conditions. After incubation, add citric acid to each well, shake to adjust pH to 3.5, take 500µl of each culture, dispense into microcentrifuge tube, and add 700ace of ethylacetate and shake for 10 minutes. Take 500µl of Ethylacetate layer and concentrate for 20 minutes using a speed vacuum dryer. The concentrated residue is dissolved in 20µl ethylacetate and applied with authentic standard on TLC plate. Radioactive bands were identified by authentic eicosanoid standards and radioactivity of the identified bands was measured by BAS 2000 bio-imaging analyzer (Table 8).

sample COX activity (%) LPS (1 μg / ml) 100 LPS (1 μg / mL) + Preprioca Oil (1 ppm) 82 LPS (1 μg / mL) + preprioca oil (10 ppm) 71 LPS (1 μg / mL) + Preprioca Oil (50 ppm) 62

As shown in Table 8, it can be seen that the priprioka oil effectively inhibits the activity of COX. It can be seen that there is an inflammation inhibitory effect.

Example 9: Evaluation of Immunosuppressive Capacity

Whether the samples used in the present invention inhibit the immune related responses associated with inflammation was examined again through IL-2 luciferase reporter activity experiments. The IL-2 promoter is reported to play an important role in the production of immune-related cytokines associated with inflammation. In order to measure IL-2 luciferase activity, the following method was used. After dispensing 1 × ¹⁰ 6 cells into 6 wells of Jurkat cells, a human T lymphocyte cell line, IL-2 luciferase reporter plasmid DNA (IL-2) was prepared using a superfect transfection reagent. luciferase reporter plasmid DNA) was transfected. After 24 hours after transfection, PHA (Phytohemaglutinin) (100 ng / ml) was treated to activate Jurkat cells, and each sample was treated by concentration. After 24 hours, cells were collected and luciferase activity was measured using a luminometer. The results are as follows.

sample IL-2 luciferase activity (%) PHA (100ng / ml) 100 PHA (100 ng / ml) + preprioca oil (1 ppm) 102 PHA (100 ng / ml) + preprioca oil (10 ppm) 91 PHA (100 ng / ml) + preprioca oil (50 ppm) 75

As shown in Table 9, it can be seen that the priprioka oil has an immunomodulatory function by inhibiting the expression of interleukin-2.

Example 10 Anti-obesity Effect

Obesity inhibition test was generally carried out by the following method using a well-known animal. The results are shown in the table.

(Method for Measuring Obesity Inhibition Activity) Crj: 7 weeks old male ICR mice (Nippon Duns River Co., Ltd.) were preliminarily bred for 1 week, and then used in experiments in 7 groups. Animals are kept in a constant temperature room set at a temperature of 23 ± 1 ° C, a humidity of 55 ± 5% and an illumination time of 12 hours / day, using Rabo MR (Nipponosan) for feed and freely ingesting water. It was. Preprioca oil was prepared in liposome formulation (dissolved in 5% lecithin) to 0.1%, 1%. Each sample solution was adjusted to a concentration of 0.1 ml per 10 g of the mouse, and the dose was set to 1.5 g / kg and 1 g / kg. In addition, the control group was a 5% lecithin emulsion. Mice were fasted from the day before administration and were forcibly administered once the next day. The test period was two weeks, and body weight and general symptoms were measured and observed.

solvent Days Weight (g) No treatment Free prio oil (0.1%) Free prio oil (1%) Priprioca liposome formulation 5 31 32 31 10 37 35 34 15 43 40 38

RESULTS: Preprica oil had an anti-obesity effect. It was observed that the higher the dosage concentration, the better the efficacy.

Example 11: Hair loss prevention and hair growth effect

In order to measure the effects on the prevention of hair loss and hair growth, a test was conducted using a hydrogel base containing only preservatives and thickeners. Using the prepared hair-promoting external preparation, it was applied to hair loss sites of 10 alopecia patients due to weakening or radiation exposure twice a day for 3 months each for 3 months. As a result, it was found that there were excellent effects such as the development of new hair roots in eight hair loss patients. The test results are as follows. As a control, moxidil sold in Hanmi Pharm was used.

No treatment group Moxidil Friprioca oil - ++ ++
-: No effect, +: good, ++: very good
As can be seen in Table 11, it can be seen that the preprioka oil of the present invention exhibits similar hair regrowth efficacy as moxidil sold as a hair regrowth agent.

According to the present invention, the priprioca oil has excellent melanin production inhibition rate and arranging collagen synthesis and inhibiting collagenase activity compared to the arbutin known as a whitening agent. In addition, no toxicity or irritation occurred in human safety tests, which proved to be safe for human use. In addition, it has been found to have an immunomodulatory effect, anti-inflammatory effect, antioxidant effect, obesity inhibitory effect, hair loss prevention and hair growth effect. Therefore, the priprioca oil of the present invention can be usefully used for cosmetics, medicine or food for various purposes as well as wrinkle improvement and whitening effects.

Claims (12)

Wrinkle improvement composition comprising a priprioca oil (priprioca oil) as an active ingredient. A composition for skin whitening comprising priprioka oil as an active ingredient. Inflammation inhibiting composition comprising a priprioka oil as an active ingredient. Anti-obesity pharmaceutical composition comprising a priprioka oil as an active ingredient. Immunosuppressive composition comprising preprioca oil as an active ingredient. A composition for promoting hair growth and preventing hair loss comprising priprioka oil as an active ingredient. Antioxidant cosmetic composition comprising a priprioka oil as an active ingredient. The composition of claim 7 wherein the composition is from the group consisting of solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, soaps, surfactant-containing cleansing oils, powder foundations, emulsion foundations, wax foundations and sprays. Cosmetic composition, characterized in that it has a formulation selected. 8. A composition according to any one of the preceding claims wherein said preprioca oil comprises from 0.0001 to 10% by weight relative to the total weight of the total composition. The composition according to any one of claims 1 to 3, 5 and 6, wherein the composition is a cosmetic composition. The composition of claim 10 wherein the composition is from the group consisting of solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, soaps, surfactant-containing cleansing oils, powder foundations, emulsion foundations, wax foundations and sprays. A composition characterized by having the formulation selected. The composition of any one of claims 1 to 6, wherein the composition is a pharmaceutical composition.

Images